The Biotechnologische Studenteninitiative (btS) held a panel discussion in the Berlin as part of its ScieCon job fair. Its aim was to have representatives from the various stakeholders exchange views on the judgment of the European Court of Justice (ECJ) regarding the regulation of organisms modified by new and innovative breeding techniques such as CRISPR-Cas9.
Similar to a request of the Federal Office of Consumer Protection and Food Safety (BVL) (see here), the Federal Ministry of Health (BMG) asked BIO Deutschland in late January 2019 to deliver an opinion. This again concerned whether the recent judgment of the European Court of Justice (ECJ) – stipulating that organisms whose genome was edited using new molecular genome-modifying techniques are to be classified as genetically modified organisms (GMOs) for the purposes of the EU Directive 2001/18/EC – is also applicable to the use of GMOs in closed systems.
Last year, BIO Deutschland and seven other trade associations promoted a national e-health vision through a discussion paper, talks with several specialist policymakers and a parliamentary evening with German Health Minister Jens Spahn.